Skip to content

Effect of Gentian violet ointment and cryotherapy on cutaneous leishmaniasis treatment

Assessment of the efficacy of Gentian violet accompanied with cryotherapy in the treatment of old world cutaneous leishmaniasis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017071316557N2
Enrollment
60
Registered
2017-08-13
Start date
2015-10-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention: Applying gentian violet 1% ointment twice daily for 8 weeks besides liquid nitrogen cryospray cryotherapy weekly for 8 weeks. Intervention 2: Control: Only liquid nitrog
Treatment - Drugs
Intervention: Applying gentian violet 1% ointment twice daily for 8 weeks besides liquid nitrogen cryospray cryotherapy weekly for 8 weeks
Control: Only liquid nitrogen cryospray cryotherapy weekly for 8 weeks

Sponsors

Research Council of Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Clinical diagnosis of cutaneous leishmaniasis; Confirmation of diagnosis by direct smear or Polymerase chain reaction test Exclusion criteria: Pregnancy or Lactation; History of consumption of topical or systemic anti-leishmania medications or cryotherapy in the recent 1 month before enrolling in study; Patients with more than 10 lesions; Patients with lesions lasting more than 4 months; Lesions on the cartilages (Ear or nose)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical cure. Timepoint: 4th and 8th weeks of the study. Method of measurement: complete response defined as more than 75% reduction, partial response defined as 50%–75% reduction, and no response to treatment defined as less than 50% reduction in the size of the lesion compared with baseline. Size is measured by multiplying the longest and shortest diameters of the lesion.

Secondary

MeasureTime frame
Side effects. Timepoint: 8th week of the study. Method of measurement: Asking the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKasra Behdad

Shiraz University of Medical Sciences

kasrabehdad@yahoo.com+98 71 3231 9049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026